imphatec: Venture Capital Funding History

imphatec Ltd. is a British synthetic biology pharmaceutical company developing the first customisable-dose subcutaneous implant platform for the treatment of chronic and long-term conditions. imphatec’s implants remove the need for manual compliance with daily medication, by releasing medication into the patient over the long term, with the dose released from the implants customisable to the individual patient. The company was co-founded by Mr James P. Catt (CEO) and Dr Hassan O. J. Morad (CSO).